Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles. Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.

"This is a major milestone for the Company as manufacturing of a drug is one of the biggest hurdles in the ability of companies to market products," said Dr. Bassam Damaj, President & CEO of the Company.

In addition to the manufacturing of the product, the Company previously announced that it has established over 30,000 stores in the United States as Vendors of Record in addition to the major wholesale drug distributors in anticipation of the FDA's decision. 

"Innovus has successfully launched multiple products in the U.S. and we have the needed expertise and know how to make it happen for FlutiCare™ if approved by the FDA," continued Dr. Damaj.

"While the ANDA is under review, the manufacturing agreement is in place and the vendors of record are established. We await the FDA's decision and are fully prepared to go full speed with the sales and marketing if the drug is approved," said Dr. Damaj.

FlutiCare™ targets the allergic and non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" by the general public. The company's FlutiCare™ active is the #1 nasal steroid prescribed by physicians and used by patients after dispensing more than 177 million units since 2007. According to a report by Fierce Pharma, GSK's Flonase OTC sold over $100,000M in a short period of time from its launch confirming the size of the market and the potential of FlutiCare™ if approved by the FDA.

About FlutiCare™
Fluticasone propionate 50 mcg spray is the No. 1 prescribed allergy treatment ingredient [1] for temporary relief of the symptoms of hay fever or upper respiratory allergies. [2]

Roughly 50 million people in the United States suffer from nasal allergies [3], and allergies take a toll on sufferers:

-- Nasal allergies can lead to fatigue, sleep disturbances, learning and attention problems and impaired function at work and/or school. [4]